Shortly after the Spring Festival was over, many medical and pharmaceutical experts from Beijing flew to Wenshan and discussed about intensive development of the panax pseudoginseng and "Daphne phenomenon". In the end, they reached a consensus with the Daphne Co.: to further optimize the capital structure, widen the financing channels and absorb more investors to construct a unique and professional modern enterprise integrating research, development, production and sales of panax pseudoginseng, and develop the Daphne Co. into a large enterprise group integrating the R&D, industrial production, trading and investment business. 
The Daphne Co., founded in May 1994 with registered capital of RMB 1.87 million yuan, has developed from a private individual owned share-limited enterprise engaged in production of common drugs to an industrial leader mainly focused on R&D and production of tPNS-based famous natural drug products. Daphne has brought out tPNS tablets (Thrombosis), tPNS granules, panax pseudoginseng anthosin, Qiye Sleep Tablets, Heart Protection Capsules (compound tPNS capsules), and Menses Protection Tablets. What's notable, they took the lead in China by launching the high-tech Qishengli and Qishengjing tablets on the basis of research and development of the monomer ingredients in the tPNS. The Company's stock capital has expanded from RMB 1.87 million yuan to RMB 10.3 million yuan. Now, the company leads the industry with its main products, varieties and brand image. It has been certified by the state regulator for GMP compliance, and listed as a high-tech enterprise and a top 100 enterprise in Yunnan. The 2000 sales income hit RMB 100 million yuan.
After restructured into a stock company, the number of shares was increased to 15480000, and the assets converted to shares were paid by 10 sponsors, says Tang Xiuwen, Daphne's Chairman. The company will further improve its capital operating ability, and better tap the local panax pseudoginseng resource to develop more high-tech natural drugs of various forms. For this purpose, they will establish a normalized governance structure, modern enterprise system, market-oriented technical innovation system and management innovation mechanism. Through cooperation with the Yunnan provincial natural drug development center, they will construct a provincial natural drug development center named the Daphne research institute, which will be a move to increase the product's technical level, develop Daphne's name product, and form a name product group. On the basis of the existing advantages in panax pseudoginseng research, development and production, they will focus on development of natural drugs for prevention and curing of cardio-cerebrovascular diseases, tumors, senile diseases, commonly seen diseases and frequently occurred diseases. A national marketing system integrating advertising & PR network, product sales network and after-sale service network will also be established, in a bid to realize gross industrial output of RMB 350 million yuan within 2 years, with sales income of RMB 320 million yuan, profit & tax of RMB 70 million yuan, and annual export earning of USD 1 million, in a bid to jump onto the list of national top 100 pharmaceutical enterprises in terms of comprehensive economic indicators and provincial top 100 industrial enterprises, and get listed someday.

(Source: February 4, 2001 issue of Dianchi Morning and Yunnan Daily)